Nevertheless, the exact mechanisms underlying the association between HCQ/CQ use and macular diseases remain incompletely understood and warrant further investigation ( Some of these adverse events have been previously documented in the drug labeling information
Analogi GLP-1 odpowiadaj na wiele z tych problemw jednoczenie
One built specifically around weight loss outcomes, with real clinical data behind every number
Of the 52 excluded records, 28 were duplicates, 15 had no results, 3 had a study duration of less than 24 weeks, 2 were non-RCTs and one did not include patients with T2D
10.1074/jbc.M205636200 16
As a result, several studies of alogliptin, sitagliptin, and saxagliptin were performed to determine CV safety in high-risk patients